Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Melanoma 350Carcinoma, Non-Small-Cell Lung 81Skin Neoplasms 72Carcinoma, Renal Cell 51Lung Neoplasms 50Neoplasm Metastasis 47Breast Neoplasms 46Colorectal Neoplasms 45Carcinoma, Basal Cell 43Neoplasms 42Uveal Melanoma 38Squamous Cell Carcinoma of Head and Neck 37Carcinoma, Merkel Cell 36Ovarian Neoplasms 35Sarcoma 32Lymphoma, T-Cell, Cutaneous 31Pancreatic Neoplasms 26Prostatic Neoplasms 24Carcinoma, Hepatocellular 23Head and Neck Neoplasms 22Stomach Neoplasms 21Uterine Cervical Neoplasms 20Urinary Bladder Neoplasms 20Thyroid Neoplasms 20Esophageal Neoplasms 19Carcinoma, Squamous Cell 18Brain Neoplasms 18Carcinoma, Transitional Cell 17Mycosis Fungoides 16Triple Negative Breast Neoplasms 15

Interventions

Paroxetine 1Itraconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lethal Congenital Contracture Syndrome 2 × Dermatologic × 90 days × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡